Company intelligence / Profile preview

Resono Ophthalmic

Ownership: Private
Development stage: Commercial

Overview

Resono Ophthalmic commercializes Rexon-Eye, a patented medical device for the treatment of dry eye disease, underpinned by QMR technology. Clinical studies have enrolled over 2,300 patients; results suggest effective, biologically safe improvement across all major dry eye subtypes, though specifics of peer-reviewed efficacy are not detailed in public summaries or available sources.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Resono Ophthalmic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resono Ophthalmic.

Explore the full profile